---
layout: default
title: Cytarabine
description: "Cytarabine çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 9 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 53
evidence_level: L2
indication_count: 9
---

# Cytarabine

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>9</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Cytarabine è—¥å¸«ç­†è¨˜

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Cytarabine å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Cytarabine (Ara-C) æ˜¯æ²»ç™‚æ€¥æ€§ç™½è¡€ç—…çš„æ ¸å¿ƒåŒ–ç™‚è—¥ç‰©ï¼ŒTxGNN é æ¸¬å…¶å°å°ç´°èƒè‚ºç™ŒåŠåŸç™¼æ€§è‚ºæ·‹å·´ç˜¤æœ‰ç™‚æ•ˆï¼Œé€™äº›é æ¸¬æœ‰æ­·å²è‡¨åºŠç ”ç©¶æ”¯æŒï¼Œä½†ç™‚æ•ˆæœ‰é™ä¸”éç¾ä»£æ¨™æº–æ²»ç™‚ã€‚
</p>

---

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥ç‰©åç¨± | Cytarabine (é˜¿ç³–èƒè‹·, Ara-C) |
| DrugBank ID | DB00987 |
| å°ç£å•†å“å | è¤‡æ–¹è£½åŠ‘ä¸­çš„æˆåˆ†ï¼Œå¦‚ Midostaurin ä½µç”¨æ–¹æ¡ˆ |
| åŸæ ¸å‡†é©æ‡‰ç—‡ | æ€¥æ€§éª¨é«“æ€§ç™½è¡€ç—… (AML)ã€æ…¢æ€§æ·‹å·´çƒæ€§ç™½è¡€ç—… (CLL)ã€èˆ‡å…¶ä»–è—¥ç‰©ä½µç”¨ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | small cell lung carcinomaã€primary pulmonary lymphomaã€well-differentiated fetal adenocarcinoma of the lungã€pulmonary blastomaã€myeloid leukemiaã€upper aerodigestive tract neoplasmã€ganglioneuroblastoma (disease)ã€vertebral anomalies and variable endocrine and T-cell dysfunctionã€è…¹è†œå¾Œè…«ç˜¤ |
| æœ€é«˜é æ¸¬åˆ†æ•¸ | 0.998 (small cell lung carcinoma) |
| è­‰æ“šç­‰ç´š | L3 (æ­·å²è‡¨åºŠç ”ç©¶ï¼Œéç¾ä»£æ¨™æº–) |

---



## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. small cell lung carcinoma</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.78%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p>Cytarabine çš„æŠ—è…«ç˜¤æ©Ÿè½‰æ”¯æŒå…¶å°å¤šç¨®æƒ¡æ€§è…«ç˜¤çš„æ½›åœ¨æ´»æ€§ï¼š</p>

<ol>
<li><strong>æ ¸è‹·é¡ä¼¼ç‰©</strong>ï¼šCytarabine æ˜¯èƒå˜§å•¶æ ¸è‹·çš„é¡ä¼¼ç‰©ï¼Œå¹²æ“¾ DNA åˆæˆ</li>
<li><strong>S æœŸç‰¹ç•°æ€§</strong>ï¼šä¸»è¦ä½œç”¨æ–¼ DNA åˆæˆæœŸï¼Œå°å¿«é€Ÿåˆ†è£‚çš„è…«ç˜¤ç´°èƒæœ‰é¸æ“‡æ€§</li>
<li><strong>å»£è­œæ´»æ€§</strong>ï¼šæ­·å²ä¸Šæ›¾ç”¨æ–¼å¤šç¨®æƒ¡æ€§è…«ç˜¤çš„æ¢ç´¢æ€§æ²»ç™‚</li>
</ol>

<h3>è‡¨åºŠè©¦é©—</h3>

<p>### å°ç´°èƒè‚ºç™Œç›¸é—œè©¦é©—</p>

<table>
<thead>
<tr>
<th>è©¦é©—ç·¨è™Ÿ</th>
<th>æ¨™é¡Œ</th>
<th>éšæ®µ</th>
<th>ç‹€æ…‹</th>
<th>ç›¸é—œæ€§</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03507244</td>
<td>é˜å…§ Pemetrexed æ²»ç™‚è…¦è†œè½‰ç§»</td>
<td>Phase 1/2</td>
<td>å·²å®Œæˆ</td>
<td>æåŠ cytarabine ä½œç‚ºå°ç…§</td>
</tr>
<tr>
<td>NCT03101579</td>
<td>é˜å…§ Pemetrexed æ²»ç™‚ NSCLC è…¦è†œè½‰ç§»</td>
<td>Phase 1</td>
<td>å·²å®Œæˆ</td>
<td>Cytarabine ä½œç‚ºå‚³çµ±é˜å…§æ²»ç™‚æ¯”è¼ƒ</td>
</tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»</h3>

<p>### å°ç´°èƒè‚ºç™Œ</p>

<table>
<thead>
<tr>
<th>PMID</th>
<th>æ¨™é¡Œ</th>
<th>å¹´ä»½</th>
<th>ä¸»è¦ç™¼ç¾</th>
</tr>
</thead>
<tbody>
<tr>
<td>232239</td>
<td>Combination radiotherapy and chemotherapy for SCLC</td>
<td>1979</td>
<td>Ara-C ä½µç”¨æ–¹æ¡ˆæœ‰æ•ˆä½†ç„¡å„ªå‹¢</td>
</tr>
<tr>
<td>3030547</td>
<td>High-dose cytarabine in SCLC</td>
<td>1987</td>
<td>é«˜åŠ‘é‡ Ara-C å–®ç¨ä½¿ç”¨åæ‡‰æœ‰é™</td>
</tr>
<tr>
<td>6095640</td>
<td>Intensive cytosine arabinoside therapy in SCLC</td>
<td>1984</td>
<td>Ara-C åŠ å…¥ CAV æ–¹æ¡ˆç„¡é¡å¤–ç›Šè™•</td>
</tr>
<tr>
<td>2841844</td>
<td>VP-16 and Ara-C for relapsed SCLC</td>
<td>1988</td>
<td>å¾©ç™¼ SCLC æ²»ç™‚ï¼Œæ¯’æ€§é«˜ä½†æ´»æ€§æœ‰é™</td>
</tr>
</tbody>
</table>

<p><strong>æ–‡ç»çµè«–</strong>ï¼š1980 å¹´ä»£çš„ç ”ç©¶é¡¯ç¤º cytarabine å° SCLC æœ‰ä¸€å®šæ´»æ€§ï¼Œä½†ä¸¦æœªå„ªæ–¼ç•¶æ™‚çš„æ¨™æº–æ–¹æ¡ˆï¼Œä¸”æ¯’æ€§é¡¯è‘—ã€‚</p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. primary pulmonary lymphoma</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.78%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ7 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00345865" target="_blank">NCT00345865</a></td><td>PHASE2</td><td>COMPLETED</td><td>473</td><td>Autologous Peripheral Blood Stem Cell Transplant for Patients With Lymphoma</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01476839" target="_blank">NCT01476839</a></td><td>PHASE1</td><td>COMPLETED</td><td>25</td><td>Phase I Study of Yttrium-90 Labeled Anti-CD25 (a-Tac) Monoclonal Antibody Plus B...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02356159" target="_blank">NCT02356159</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>34</td><td>A Phase I/II Open Label, Dose Escalation Study of Palifermin (Kepivance) in Pers...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00013533" target="_blank">NCT00013533</a></td><td>EARLY_PHASE1</td><td>COMPLETED</td><td>30</td><td>Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantati...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00452374" target="_blank">NCT00452374</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>48</td><td>A Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Pati...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 2 é …è©¦é©—</em></p>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26256690/" target="_blank">26256690</a></td><td>2017</td><td>Article</td><td>The clinical respira</td><td>Synchronous mantle cell lymph node lymphoma and pulmonary ad...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15957966/" target="_blank">15957966</a></td><td>2005</td><td>Article</td><td>Expert opinion on ph</td><td>Management of leptomeningeal malignancy.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12860951/" target="_blank">12860951</a></td><td>2003</td><td>Article</td><td>Journal of clinical </td><td>Chemotherapy alone as initial treatment for primary CNS lymp...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11244328/" target="_blank">11244328</a></td><td>2001</td><td>Article</td><td>Oncology</td><td>Combined treatment with high-dose methotrexate, vincristine ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38555923/" target="_blank">38555923</a></td><td>2024</td><td>Article</td><td>The Lancet. Haematol</td><td>Anti-CD30 CAR T cells as consolidation after autologous haem...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. well-differentiated fetal adenocarcinoma of the lung</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.76%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. pulmonary blastoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.76%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. upper aerodigestive tract neoplasm</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.49%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32183950/" target="_blank">32183950</a></td><td>2020</td><td>Article</td><td>Cancer cell</td><td>ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulatin...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16041392/" target="_blank">16041392</a></td><td>2005</td><td>Article</td><td>The pharmacogenomics</td><td>Genetic factors influencing pyrimidine-antagonist chemothera...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36656600/" target="_blank">36656600</a></td><td>2023</td><td>Article</td><td>JAMA oncology</td><td>Malignant Neoplasms of the Gastrointestinal Tract After Bloo...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2589230/" target="_blank">2589230</a></td><td>1989</td><td>Article</td><td>American journal of </td><td>Combination chemotherapy with cytosine arabinoside (Ara-C) a...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15548350/" target="_blank">15548350</a></td><td>2004</td><td>Article</td><td>Neoplasia (New York,</td><td>Chemotherapy-induced and/or radiation therapy-induced oral m...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. ganglioneuroblastoma (disease)</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.36%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. vertebral anomalies and variable endocrine and T-cell dysfunction</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.32%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. retroperitoneal neoplasm</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.23%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ1 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01468311" target="_blank">NCT01468311</a></td><td>PHASE1, PHASE2</td><td>TERMINATED</td><td>6</td><td>Phase I/II Trial of Yttrium-90-labeled Daclizumab (Anti-CD25) Radioimmunotherapy...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ14 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34733617/" target="_blank">34733617</a></td><td>2021</td><td>Article</td><td>World journal of cli</td><td>Gastric myeloid sarcoma: A case report.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12656749/" target="_blank">12656749</a></td><td>2003</td><td>Article</td><td>European journal of </td><td>Acute myeloid leukemia mimicking primary testicular neoplasm...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16632190/" target="_blank">16632190</a></td><td>2007</td><td>Article</td><td>European urology</td><td>Retroperitoneal fibrosis after chemotherapy.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28579851/" target="_blank">28579851</a></td><td>2017</td><td>Article</td><td>Clinical medicine in</td><td>Transformation of Follicular Lymphoma to a High-Grade B-Cell...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2049752/" target="_blank">2049752</a></td><td>1991</td><td>Article</td><td>Cancer</td><td>Improved treatment results in boys with overt testicular rel...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 9 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. neuroblastoma</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.19%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ5 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04029688" target="_blank">NCT04029688</a></td><td>PHASE1, PHASE2</td><td>TERMINATED</td><td>38</td><td>A Phase I/II, Multicenter, Open-Label, Multi-Arm Study Evaluating the Safety, To...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03236857" target="_blank">NCT03236857</a></td><td>PHASE1</td><td>COMPLETED</td><td>143</td><td>A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric an...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02130869" target="_blank">NCT02130869</a></td><td>PHASE1</td><td>COMPLETED</td><td>8</td><td>A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Followi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01546038" target="_blank">NCT01546038</a></td><td>PHASE2</td><td>COMPLETED</td><td>255</td><td>A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-04449913, AN ORAL H...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06942039" target="_blank">NCT06942039</a></td><td>EARLY_PHASE1</td><td>RECRUITING</td><td>15</td><td>A Pilot Study of Intrathecal Topotecan and Maintenance Chemotherapy in the Post-...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36688816/" target="_blank">36688816</a></td><td>2023</td><td>Article</td><td>ACS applied material</td><td>Green Light-Triggerable Chemo-Photothermal Activity of Cytar...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15867251/" target="_blank">15867251</a></td><td>2005</td><td>Article</td><td>Clinical cancer rese</td><td>Sensitivity to gemcitabine and its metabolizing enzymes in n...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31681584/" target="_blank">31681584</a></td><td>2019</td><td>Article</td><td>Frontiers in oncolog</td><td>Two Receptors, Two Isoforms, Two Cancers: Comprehensive Anal...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/7529082/" target="_blank">7529082</a></td><td>1993</td><td>Article</td><td>Cancer biotherapy</td><td>Sensitivity to bleomycin and arabinoside cytosine in lymphoc...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2917605/" target="_blank">2917605</a></td><td>1989</td><td>Article</td><td>Experimental cell re</td><td>Morphologic and phenotypic changes of human neuroblastoma ce...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

Cytarabine åœ¨å°ç£ä¸»è¦ä»¥ä¸‹åˆ—å½¢å¼ä½¿ç”¨ï¼š

| ç”¨é€” | è—¥å“ | èªªæ˜ |
|------|------|------|
| AML å‰å°æ²»ç™‚ | Midostaurin (å½Œå¤šå¦¥) ä½µç”¨ | FLT3 çªè®Šé™½æ€§ AML |
| AML éå›ºæ²»ç™‚ | é«˜åŠ‘é‡ Ara-C | æ¨™æº–æ–¹æ¡ˆ |
| CLL æ²»ç™‚ | Venetoclax ä½µç”¨ä½åŠ‘é‡ Ara-C | ä¸é©åˆå¼·åŒ–åŒ–ç™‚çš„æ‚£è€… |

---

## å®‰å…¨æ€§è€ƒé‡

### ä¸»è¦æ¯’æ€§

| æ¯’æ€§é¡å‹ | è¡¨ç¾ | ç®¡ç† |
|----------|------|------|
| éª¨é«“æŠ‘åˆ¶ | åš´é‡å—œä¸­æ€§çƒä½ä¸‹ã€è¡€å°æ¿ä½ä¸‹ | ç›£æ¸¬ CBCï¼Œé é˜²æ€§ä½¿ç”¨ G-CSF |
| æ„ŸæŸ“ | æ©Ÿæœƒæ€§æ„ŸæŸ“é¢¨éšªé«˜ | é é˜²æ€§æŠ—ç”Ÿç´ ã€æŠ—é»´èŒè—¥ |
| ç¥ç¶“æ¯’æ€§ | é«˜åŠ‘é‡æ™‚å¯èƒ½å‡ºç¾å°è…¦ç—‡ç‹€ | ç›£æ¸¬ç¥ç¶“åŠŸèƒ½ï¼Œèª¿æ•´åŠ‘é‡ |
| æ¶ˆåŒ–é“ | é»è†œç‚ã€å™å¿ƒå˜”å | æ­¢åè—¥ã€å£è…”è­·ç† |
| Ara-C ç—‡å€™ç¾¤ | ç™¼ç‡’ã€è‚Œç—›ã€éª¨ç—›ã€çš®ç–¹ | é¡å›ºé†‡é é˜² |

### è—¥ç‰©äº¤äº’ä½œç”¨æ³¨æ„

- **å…¶ä»–éª¨é«“æŠ‘åˆ¶è—¥ç‰©**ï¼šæ¯’æ€§ç–ŠåŠ 
- **Digoxin**ï¼šå¯èƒ½é™ä½ digoxin å¸æ”¶
- **Flucytosine**ï¼šç«¶çˆ­æ€§æ‹®æŠ—

---


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**è‚è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šCytarabine is extensively metabolized by the liver...

**è…è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šCytarabine is primarily eliminated by the kidney...

**Infections** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šéª¨é«“æŠ‘åˆ¶ã€æ„ŸæŸ“ã€‚

**Bone Marrow Failure Disorders** ğŸŸ¢ Minor
- é¢¨éšªåŒ…æ‹¬ï¼šéª¨é«“æŠ‘åˆ¶ã€å‡ºè¡€ã€æ„ŸæŸ“ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### é æ¸¬è©•ä¼°

| è©•ä¼°é …ç›® | å°ç´°èƒè‚ºç™Œ | åŸç™¼æ€§è‚ºæ·‹å·´ç˜¤ |
|----------|------------|----------------|
| æ©Ÿè½‰åˆç†æ€§ | é«˜ | é«˜ |
| è‡¨åºŠè­‰æ“š | L3 (æ­·å²ç ”ç©¶) | L2 (CNS æ·‹å·´ç˜¤æœ‰ RCT) |
| æ–‡ç»æ”¯æŒ | ä¸­ç­‰ä½†éæ™‚ | è¼ƒå¼·ï¼ˆç”¨æ–¼ CNS æ·‹å·´ç˜¤ï¼‰ |

### è‡¨åºŠæ„ç¾©è©•ä¼°

#### å°ç´°èƒè‚ºç™Œ

- **ä¸å»ºè­°è‡¨åºŠä½¿ç”¨**ï¼šç¾ä»£ SCLC æ²»ç™‚å·²ä¸åŒ…å« cytarabine
- **ç¾ä»£æ¨™æº–**ï¼šCisplatin/Carboplatin + Etoposideï¼Œå…ç–«æ²»ç™‚ (å¦‚ atezolizumab)
- **æ­·å²åƒ¹å€¼**ï¼šåæ˜ äº†çŸ¥è­˜åœ–è­œèƒ½æ•æ‰æ­·å²ç”¨è—¥é—œè¯

#### åŸç™¼æ€§è‚ºæ·‹å·´ç˜¤/CNS æ·‹å·´ç˜¤

- **æœ‰è‡¨åºŠåƒ¹å€¼**ï¼šé«˜åŠ‘é‡ Ara-C æ˜¯ CNS æ·‹å·´ç˜¤æ²»ç™‚çš„é‡è¦æˆåˆ†
- **ç¾ä»£æ–¹æ¡ˆ**ï¼šé€šå¸¸èˆ‡ MTXã€rituximab ä½µç”¨
- **æ³¨æ„äº‹é …**ï¼šã€ŒåŸç™¼æ€§è‚ºæ·‹å·´ç˜¤ã€è¼ƒç½•è¦‹ï¼Œæ²»ç™‚é€šå¸¸åƒè€ƒå…¨èº«æ€§æ·‹å·´ç˜¤æ–¹æ¡ˆ

### å»ºè­°

1. **SCLC**ï¼šä¸å»ºè­°ä½¿ç”¨ cytarabineï¼Œæ‡‰ä¾å¾ªç¾ä»£æ²»ç™‚æŒ‡å¼•
2. **CNS æ·‹å·´ç˜¤**ï¼šé«˜åŠ‘é‡ cytarabine ä»æœ‰å…¶è§’è‰²ï¼Œéœ€ç”±è¡€æ¶²è…«ç˜¤å°ˆç§‘è©•ä¼°
3. **è…¦è†œè½‰ç§»**ï¼šé˜å…§ cytarabine æˆ– liposomal cytarabine ç‚ºå¯é¸æ–¹æ¡ˆ

### æ•´é«”è­‰æ“šç­‰ç´š

**L3 (è§€å¯Ÿæ€§ç ”ç©¶/æ­·å²è‡¨åºŠç¶“é©—)** - æœ‰æ–‡ç»æ”¯æŒä½†éç¾ä»£æ¨™æº–æ²»ç™‚

---

*æœ¬ç­†è¨˜åƒ…ä¾›ç ”ç©¶åƒè€ƒï¼Œä¸æ§‹æˆé†«ç™‚å»ºè­°ã€‚ä»»ä½•ç”¨è—¥æ±ºç­–æ‡‰è«®è©¢å°ˆæ¥­é†«ç™‚äººå“¡ã€‚*

*æœ€å¾Œæ›´æ–°ï¼š2026-02-11*

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Raloxifene]({{ "/drugs/raloxifene/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Brivaracetam]({{ "/drugs/brivaracetam/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Flunitrazepam]({{ "/drugs/flunitrazepam/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Clomipramine]({{ "/drugs/clomipramine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Tenofovir Alafenamide]({{ "/drugs/tenofovir_alafenamide/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Cytarabineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/cytarabine/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_cytarabine,
  title = {Cytarabineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/cytarabine/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
